Drug intelligence / Profile preview

hNPCEX

Development stage: Preclinical
Lead developer: Hopstem Biotechnology
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

hNPCEX is an investigational exosome-based therapy developed by Hopstem Biotechnology, derived from human neural progenitor cells (hNPCs). This therapy utilizes extracellular vesicles to deliver therapeutic cargo, including proteins and nucleic acids, to the central nervous system. It is currently in development for the treatment of Autism Spectrum Disorder and Alzheimer's Disease. The mechanism is thought to involve the modulation of neuroinflammation, enhancement of synaptic plasticity, and promotion of neuroregeneration, leveraging the innate regenerative potential of neural progenitor cell signaling.

Beyond the preview

Go deeper on hNPCEX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hNPCEX.

Explore the full profile